Pharmaceutical Netherlands-based Pharming Group has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Ruconest [recombinant human C1 esterase inhibitor/conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE). 27 November 2017